Novocure wins FDA nod for pivotal pancreatic cancer trial

The FDA has given Novocure (NSDQ:NVCR) the green light to bring the company’s Tumor Treating Fields tech into a pivotal Phase III pancreatic cancer trial.

The 556-patient study is designed to assess the safety and efficacy of Novocure’s TTFields combined with nab-paclitaxel and gemcitabine as a front-line treatment for unresectable locally-advanced pancreatic cancer.

Get the full story at our sister site, Drug Delivery Business News.

The post Novocure wins FDA nod for pivotal pancreatic cancer trial appeared first on MassDevice.

from MassDevice http://ift.tt/2B76LeN